Stinchcombe TE, Roder J ... Moore DT, Socinski MA, J Thorac Oncol, Jan 30, 2013
In a multicenter randomized phase II trial of gemcitabine (arm A), erlotinib (arm B), and gemcitabine and erlotinib (arm C), similar progression-free survival (PFS) and overall survival (OS) were observed in all arms. We performed an exploratory, blinded, retrospective analysis of plasma or serum samples collected as part of the trial to investigate the ability of VeriStrat (VS) to predict treatment outcomes.
Gemcitabine is the superior treatment for elderly patients with VS Poor status. First-line erlotinib for elderly patients with VS Good status may warrant further investigation.
Augustin A, Lamerz J ... Essioux L, Klughammer B, Mol Cancer Ther, Jan 31, 2013
Although both erlotinib and gefitinib target the epidermal growth factor receptor (EGFR), erlotinib is effective in patients with EGFR wild-type or mutated tumors, whereas gefitinib is only beneficial for patients with activating mutations. To determine whether these differences in clinical outcomes can be attributed to their respective protein interaction profiles, a label-free, quantitative chemical proteomics study was performed. We propose that, in an EGFR wild-type context, erlotinib may have a complementary mode of action by inhibiting integrin-linked kinase (ILK), -parvin and PINCH (IPP) complex activities, resulting in the slowing down of the metastatic process of epithelial tumors.
Majhi PD, Lakshmanan I ... Batra SK, Ganti AK, J Thorac Oncol, Jan 30, 2013
Altered expression of MUC4 plays an oncogenic role in various cancers, including pancreatic, ovarian, and breast. This study evaluates the expression and role of MUC4 in non-small-cell lung cancer (NSCLC).
MUC4 plays a tumor-suppressor role in NSCLC by altering p53 expression in NSCLC. Decrease in MUC4 expression in advanced tumor stages also seems to confirm the novel protective function of MUC4 in NSCLC.
Gupta A, Das S ... Choudhuri KB, Maiti S, J Phys Pharm Adv, Jan 2013
The objective of this research was to identify impact of risk factors on changing trends of lung cancer in a case control study. In the study conducted from 2006 to 2010 the cases included newly diagnosed patients of histological proven lung carcinoma attending the radiotherapy department. Change in trend was observed in patients diagnosed at younger age of 57.48 ± 0.56 years in 2010 with adenocarcinoma unlike 62.89 ± 1.21 years in 2006. Females show increase in incidence of lung cancer in 2010. The “active” smokers and years of smoking were significantly high among cases. The incidence of squamous cell carcinoma declined from 47.4% in 2006 to 15% in 2010 whereas adenocarcinoma increased.
Burns TF, Dobromilskaya I ... Tran PT, Rudin CM, Mol Cancer Res, Jan 30, 2013
We recently demonstrated that the basic helix-loop-helix transcription factor Twist1 cooperates with mutant Kras to induce lung adenocarcinoma in transgenic mouse models and that inhibition of Twist1 in these models led to Kras-induced senescence. In the current study, we show that silencing of TWIST1 in KRAS mutant human NSCLC cell lines as well as in in EGFR mutation driven and c-Met amplified NSCLC cell lines resulted in dramatic growth inhibition and either activation of a latent oncogene-induced senescence program or in some cases, apoptosis.These findings suggest that silencing of TWIST1 in oncogene driver dependent NSCLC represents a novel and promising therapeutic strategy.
CollabRx, Inc. announced the release of a new version of its Therapy Finder™application (“app”) for lung cancer. The lung cancer Therapy Finder™app is a web-based decision support tool that enables oncologists to take into account the genetics of a patient’s tumor when determining a treatment plan. The newest lung cancer Therapy Finder™ is currently freely available at the company’s website and via distribution partners such as MedPage Today, Everyday Health’s physician portal.
Oncolytics Biotech Inc said a mid-stage trial of its experimental lung cancer drug showed that 95 percent of the patients experienced a reduction in the size of their tumors. The drug, Reolysin, was used intravenously in combination with chemotherapy drugs carboplatin and paclitaxel. It was tested on patients suffering from metastatic or recurrent squamous cell carcinoma of the lung.
Ying J, Rahbar MH ... Forman MR, Gorlova OY, PLoS One, Feb 1, 2013
Evidence from human and animal research indicates that choline metabolic pathways may be activated during a variety of diseases, including cancer. We report results of a case-control study of 2821 lung cancer cases and 2923 controls that assessed associations of choline and betaine dietary intakes with lung cancer. Our results suggest that choline and betaine intake, especially higher betaine intake, may be protective against lung cancer through mitigating the adverse effect of smoking.